Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fondazione Italiana Linfomi - ETS
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient with a history of classical HL relapsed/refractory which received IGEV regimen as induction therapy before high dose chemotherapy with AHSCT
Age \>18 years
Patients with relapsed/refractory disease after standard treatments (chemotherapy +/- radiotherapy) before IGEV induction regimen. (Relapsed = disease relapse after CR.
Refractory = non CR with last chemotherapy line, or progression during last treatment, or disease progression within three months from previous treatment completion).
Availability of clinical data, laboratory values and CT scan results of patients enrolled, performed from diagnosis to the last follow-up
Patient scheduled to receive three or four IGEV cycles as pretransplantation induction regimen.
First IGEV course started before December 31st 2007
Assessment of tumor response by Cheson 1999 criteria 11
You may not be if
NONE
Clareo Health | Prognosis of Patients With Relapsed/Refractory Hodgkin Lymphoma Treated With IGEV Induction Therapy Before HDCT With AHSCT
